Date of Award
M.S. in Pharmaceutical Science
University of Mississippi
The goal of the present study was to develop a nanoemulsion (NE) system for efficient and prolonged delivery of Fingolimod Hydrochloride (FTY720; FT), to the posterior segment of the eye through the topical route. FT is a sphingosine-1-phosphate receptor agonist, an immunosuppressive agent. FT loaded NE (FT-NE) formulations were prepared with the homogenization method, using Soybean oil as lipid, Tween® 80 and Poloxamer 188 as surfactants. FT-NE were optimized based on particle size, zeta potential (ZP), Polydispersity Index (PDI) and assay. optimized FT-NE formulation were further evaluated for in vitro release and transcorneal in comparison with FT solution (FT-S) formulation, sterilization and stability studies. Optimized FT-NE formulation had a drug load of 0.3% w/v, shoa particle size, PDI, ZP and assay of 174.6±1.5 nm, 0.22 ± 0.01, 32.8 ± 1.9 mV and 97.5 ± 2.5%, respectively. The filtration studies indicated negligible process loss (< 1%) when filtered through PES 0.22µm filters. FT-NE formulation was stable for 45 days and 90 days at room temperature and refrigerator conditions, respectively. In vitro release studies sho50.1 ± 6.3% and 79.2 ± 2.6% drug release from FT-NE and FT-S over 24 h, indicating sustained release. Transcorneal permeation studies sho2-fold and 5-fold increase between FT-S (0.15%) and FT-NE-S3 and FT-S (0.3%) and FT-NE-S2 formulations, respectively. The results from this study demonstrated that the NE formulation can serve as a viable platform for topical delivery of FT.
Kashikar, Rama Avinash, "Formulation And Optimization Of Fingolimog Hydrochloride Nanoemulsion" (2020). Electronic Theses and Dissertations. 1831.